Polyclonal antibody and immunogenic peptide of BAZ1B_K426hy

By designing specific sequence polypeptides and polyclonal antibodies, the problem of insufficient application of specific modification sites and polyclonal antibodies in the prior art was solved, and efficient detection of the expression of BAZ1B_K426hy protein was achieved, and specificity of tumor cells was used to achieve efficient detection of BAZ1B_K426hy protein Diagnosis provides high specificity and high sensitivity detection methods.

CN116855472BActive Publication Date: 2024-11-08TANGSHAN PEOPLES HOSPITAL +2
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310983201.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-10-21
Publication Date
2024-11-08
Estimated Expiration
2042-10-21

AI Technical Summary

Technical Problem

The prior art has not been able to effectively use specific modification sites and polyclonal antibodies/immunogenic polypeptides of the BAZ1B protein for diagnosis and detection of tumor cells, especially in the differential recognition of BAZ1B_K426hy protein expression in breast cancer and other types of tumors. insufficient.

Method used

Design and synthesize specific sequences of immunogenic polypeptides A and polypeptide B for preparation of polyclonal antibodies against BAZ1B_K426hy, specifically recognize endogenous BAZ1B_K426hy protein through ELISA/Dotblot/Western blot method, and combine KLH coupling and animal immune technology. Polyclonal antibodies with high affinity performance were obtained to detect the expression of BAZ1B_K426hy protein to diagnose tumor cells.

Benefits of technology

Through the difference in expression of BAZ1B_K426hy protein, specific diagnosis of tumor cells is achieved, and a high specificity, high sensitivity and high titer detection method is provided. It is suitable for a variety of types of tumor cells, including lung cancer, triple-negative breast cancer, Non-triple-negative breast cancer, etc.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116855472B_ABST
    Figure CN116855472B_ABST
Patent Text Reader

Abstract

The present invention provides an application of BAZ1B_K426 hydroxylation (hydroxylation, hy) in preparing a product for detecting tumors, belonging to the field of biotechnology. The present invention also provides a group of immunogenic polypeptides, including polypeptide A and polypeptide B, and a polyclonal antibody against BAZ1B_K426hy is prepared by mixing the immunogenic polypeptides with an animal for immunization. The polyclonal antibody can specifically recognize endogenous BAZ1B_K426hy protein by ELISA / Dot blot / Western blot methods, and is used for the preparation of tumor and Williams syndrome detection products.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application with an application date of October 21, 2022, application number 202211290030.1, and invention name "Application of BAZ1B_K426hy and its polyclonal antibodies in the preparation of products for tumor detection." Technical Field

[0002] The invention belongs to the field of biotechnology, and in particular relates to the application of BAZ1B_K426hy and its polyclonal antibody in the preparation of products for detecting tumors. Background Art

[0003] The BAZ1B gene (also known as the WSTF gene) is the gene encoding the transcription factor BAZ1B detected in patients with Williams syndrome. Williams syndrome is a genetic disease, and more than 20 genes are known to be associated with its onset. Studies have found that the BAZ1B gene plays a more important role than other genes in a series of systemic defects exhibited by patients. The researchers found that compared with normal control mice, mice with BAZ1B knockout were smaller in size and died a few days after birth, suggesting that this gene plays an important role in the normal growth and development of mice. Further mechanistic studies revealed that the functions of BAZ1B protein are very diverse, and the biological processes it participates in include chromatin remodeling, gene transcription and expression regulation, cell cycle and apoptosis regulation, DNA damage repair and vitamin metabolism. In terms of gene transcription regulation, the participation of BAZ1B is particularly complex. BAZ1B protein has been detected in three important ATP-dependent chromatin remodeling complexes, and has both transcriptional activation and inhibition. This makes BAZ1B considered to be at the core of chromatin regulation.

[0004] At present, studies have shown that BAZ1B can bind to the secretory protein NRG3 (neuregulin-3), be transported outside the cell, and promote the occurrence and development of colon cancer in a paracrine manner. Other studies have clarified the role of BAZ1B in regulating the occurrence and development of breast cancer and lung cancer by promoting cell proliferation and migration, and introduced BAZ1B into the field of oncology research, which has attracted close attention in this field. BAZ1B belongs to the bromodomain adjacent to azinc-fingermotif (BAZ) protein family, which has multiple domains (see Figure 1), with diverse biological functions. BAZ1B can recognize and bind to histones through the PHD (planthomeodomain), WAC (WSTF / Acf1 / cbpq46) and Bromodomain domains, and participate in the regulation of histone modifications. The WAC domain of BAZ1B has tyrosine kinase activity, which can phosphorylate the 142nd tyrosine residue of histone H2A.X, and participate in the repair or apoptosis regulation after DNA damage. Proteins containing PHD domains can usually bind to methylated Lys residues (K, Lysine, lysine) and regulate gene transcription, but the histone modification sites that specifically bind to the PHD domain of WSTF have not yet been determined. The Bromodomain domain of WSTF can bind to acetylated histones (such as H3K14Ac, H4K16Ac and H2BK12Ac) to regulate the transcription of downstream target genes.

[0005] The function of BAZ1B in promoting breast cancer cell proliferation and migration is regulated by the type and level of its post-translational modification, and BAZ1B can undergo multiple post-translational modifications at multiple sites. It has been identified in breast cancer cells that Ser158 (S, Serine, serine) and Lys426 residues of BAZ1B can be phosphorylated (S158ph) and acetylated (K426Ac) respectively. However, whether it is phosphorylation of Ser158 residue or acetylation of Lys426 residue, it positively regulates BAZ1B activity. Negative regulatory signals also play an important regulatory role in the function of proteins. Under a certain spatiotemporal specific background, the balance of negative and positive regulation can keep cells and tissues in a normal stable state. However, there are no reports on other modification sites of BAZ1B and corresponding polyclonal antibodies / immunogen peptides. Summary of the invention

[0006] The purpose of the present invention is to provide an application of BAZ1B_K426hy in the preparation of a product for detecting tumors. The occurrence of tumor cells can be diagnosed by the expression level of BAZ1B_K426hy.

[0007] The object of the present invention is to provide an immunogenic polypeptide that can be used to prepare polyclonal antibodies against BAZ1B_K426hy.

[0008] The present invention also aims to provide an anti-BAZ1B_K426hy polyclonal antibody that can specifically recognize endogenous BAZ1B_K426hy protein by ELISA / Dotblot / Western blot methods.

[0009] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

[0010] The present invention provides application of BAZ1B_K426hy in preparing a product for detecting tumors.

[0011] Preferably, the product includes antibodies, drugs and kits.

[0012] Preferably, the tumor includes lung cancer, triple-negative breast cancer, non-triple-negative breast cancer, colorectal cancer, pigmented tumor, gastric cancer, cervical cancer, glioma, esophageal cancer, ovarian cancer and pancreatic cancer.

[0013] The present invention also provides an immunogenic polypeptide for preparing a polyclonal antibody against BAZ1B_K426hy, wherein the polypeptide comprises a polypeptide A having a sequence of SKSPK-hydroxyl K-GLKTP and a polypeptide B having a sequence of NSKSPK-hydroxyl K-GLKTPK.

[0014] The present invention also provides a polyclonal antibody against BAZ1B_K426hy, wherein the polyclonal antibody is obtained by immunizing an animal with a mixture of the immunogenic polypeptides.

[0015] Preferably, polypeptide A and polypeptide B are coupled to KLH respectively and then mixed for immunization.

[0016] Preferably, the coupled polypeptide A solution and the coupled polypeptide B solution are mixed at a volume ratio of 1-2:1-2.

[0017] Preferably, the animal is a rabbit.

[0018] The present invention also provides a method for preparing the above-mentioned polyclonal antibody, comprising the following steps: coupling the above-mentioned immunogenic polypeptides with KLH respectively, mixing the coupled polypeptide solutions at a volume ratio of 1-2:1-2 and using them for animal immunization, collecting the serum of the immunized animals for purification, and obtaining a polyclonal antibody against BAZ1B_K426hy.

[0019] Preferably, the animal is immunized 3 to 5 times.

[0020] Compared with the prior art, the present invention has the following beneficial effects:

[0021] The present invention found that the Lys426 residue of BAZ1B can also undergo hydroxylation modification in tumor cells, and there is a competitive relationship with the acetylation modification at the same site. The expression level of BAZ1B_K426hy protein in tumor cells is significantly different from that in normal cells, and the occurrence of tumor cells can be diagnosed by the expression level of BAZ1B_K426hy.

[0022] The immunogenic polypeptide provided by the present invention has good immunogenicity. The anti-BAZ1B_K426hy polyclonal antibody obtained by using the polypeptide as an antigen to immunize an animal has good affinity, can specifically identify endogenous BAZ1B_K426hy protein by ELISA / Dot blot / Western blot methods, has high specificity, high sensitivity and high titer, and can be used to prepare BAZ1B_K426hy protein-related disease detection reagents. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 :Schematic diagram of the structure of WSTF (BAZ1B);

[0024] Figure 2 : Mass spectrometry detection results of BAZ1B polypeptide A;

[0025] Figure 3 : Mass spectrometry detection results of BAZ1B polypeptide B;

[0026] Figure 4 : Mass spectrometry results of BAZ1B non-modified peptide;

[0027] Figure 5 : Serum Western blot preliminary screening results;

[0028] Figure 6 :Antibody Dotblot test results;

[0029] Figure 7 : Western blot test results of antibodies, A to D represent Mouse testis, Rat testis, HeLa and MCF-7 cell lysates, respectively;

[0030] Figure 8 : Western blot detection results of Ab1 in HeLa and MCF-7 lysates;

[0031] Fig. 9 :Transwell assay results of the invasion ability of cells in each group;

[0032] Fig.10 :The clone formation experiment was used to detect the proliferation ability of each group of cells;

[0033] Fig.11 : WB detection results of BAZ1B_K426hy expression level in MCF-7 cells with JMJD6 knockdown, overexpression or mutation;

[0034] Fig.12 : WB detection results of BAZ1B_K426hy expression levels in various tumor cells. DETAILED DESCRIPTION

[0035] The present invention provides application of BAZ1B_K426hy in preparing a product for detecting tumors.

[0036] BAZ1B_K426hy described in the present invention refers to a protein modified by hydroxylation (Hy) of the Lys426 residue of WSTF (BAZ1B). The present invention found that the Lys426 residue of BAZ1B can also undergo hydroxylation modification in tumor cells, and there is a competitive relationship with the acetylation modification at the same site. Lys426 hydroxylation may be a negative regulatory modification of BAZ1B protein. Hydroxylation of this site can inhibit the transcriptional regulatory activity of WSTF and induce its degradation. There is a significant difference between the expression level of BAZ1B_K426hy protein in tumor cells and that in normal cells. The occurrence of tumor cells can be diagnosed by the expression level of BAZ1B_K426hy.

[0037] The product of the present invention includes antibodies, drugs and kits. The tumors of the present invention include lung cancer, triple-negative breast cancer, non-triple-negative breast cancer, colorectal cancer, pigment tumor, gastric cancer, cervical cancer, glioma, esophageal cancer, ovarian cancer and pancreatic cancer. The present invention compares the BAZ1B_K426hy expression in lung cancer cells, triple-negative breast cancer cells, non-triple-negative breast cancer cells, colorectal cancer cells, pigment tumor cells, gastric cancer cells, cervical cancer cells, glioma cells, esophageal cancer cells, ovarian cancer cells, pancreatic cancer cells with the BAZ1B_K426hy expression in lung epithelial cells and ovarian epithelial cells in normal cells, and finds that there is a significant difference in the BAZ1B_K426hy expression in tumor cells and normal cells, and the occurrence of tumors can be judged by detecting the BAZ1B_K426hy expression.

[0038] The present invention provides an immunogenic polypeptide, which comprises a polypeptide A having a sequence of SKSPK-hydroxyl K-GLKTP and a polypeptide B having a sequence of NSKSPK-hydroxyl K-GLKTPK. The polypeptide A and polypeptide B of the present invention are designed and synthesized according to the BAZ1B protein sequence and modification type (hydroxylation modification).

[0039] The amino acid sequence of polypeptide A of the present invention is: SKSPK-(hydroxyl)K-GLKTP C (the terminal "C" represents the carbon end of the amino acid sequence), the molecular weight is 1289.6, the sixth position "K" of the amino acid sequence is hydroxylated, the amino acid connection sequence is shown in SEQ ID NO.1, and the mass spectrometry detection results are shown in Figure 1The amino acid sequence of polypeptide B is: NSKSPK-(hydroxyl)K-GLKTPK C (the terminal "C" represents the carbon end of the amino acid sequence), the molecular weight is 1531.8, the 7th "K" of the amino acid sequence is hydroxylated, the amino acid connection sequence is shown in SEQ ID NO.2, and the mass spectrometry detection results are shown in Figure 2 .

[0040] The present invention also provides the use of the above immunogenic polypeptide in preparing polyclonal antibodies against BAZ1B_K426hy. The immunogenic polypeptide can be used for animal immunization to prepare polyclonal antibodies against BAZ1B_K426hy by coupling with KLH.

[0041] The present invention also provides a polyclonal antibody against BAZ1B_K426hy, which is obtained by immunizing an animal with the above-mentioned immunogenic polypeptide mixture. Polypeptide A and polypeptide B are coupled with KLH respectively, and the coupled polypeptide A solution and the coupled polypeptide B solution are mixed in a volume ratio of 1-2:1-2 for animal immunization. The volume ratio of the coupled polypeptide A solution to the coupled polypeptide B solution is preferably 1:1, and the animal is preferably a rabbit.

[0042] The present invention also provides a method for preparing the above-mentioned polyclonal antibody, comprising the following steps: coupling the above-mentioned immunogenic polypeptides with KLH respectively, mixing the coupled polypeptide solutions at a volume ratio of 1-2:1-2 and using them for animal immunization, collecting the serum of the immunized animals for purification, and obtaining a polyclonal antibody against BAZ1B_K426hy, wherein the number of animal immunizations is preferably 3-5 times, and more preferably 4 times.

[0043] As an optional embodiment, the antigen and adjuvant are completely mixed to form a stable emulsion, the antigen mixture is extracted with a syringe, and the antigen is injected into two points under the skin of the shoulders and two points in the muscles of the hind legs of the rabbit. About 1 / 4 volume of the immunogen emulsion in each area can ensure the persistent presence of the immunogen and thus improve the immune response. Preferably, the antigen polypeptide is diluted with physiological saline, and the dilution multiple is 10 to 20 times, more preferably 12 to 15 times; the adjuvant is Freund's adjuvant; the mixing ratio of the immunogen and the adjuvant is 1:1.

[0044] The immunogenic polypeptide or the polyclonal antibody or the method for preparing the polyclonal antibody of the present invention can be used to prepare a detection reagent for BAZ1B_K426hy protein-related diseases. Preferably, the related diseases include tumors and Williams syndrome.

[0045] The technical solutions in the present invention will be described clearly and completely below in conjunction with the embodiments of the present invention. Obviously, the described embodiments are only a part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0046] In the following embodiments, unless otherwise specified, all of them are conventional methods.

[0047] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources.

[0048] Example 1

[0049] According to the BAZ1B protein sequence and modification type, two antigenic peptides, peptide A and peptide B, were designed and synthesized for subsequent animal immunization, purification and detection; at the same time, a non-modified control peptide (SEQ ID NO.3, the terminal "C" represents the carbon end of the amino acid sequence) was designed and synthesized for purification and detection. Peptide information is shown in Table 1.

[0050] Table 1 Peptide information table

[0051]

[0052] Mass spectrometry was performed on the three sequences. Figure 2 is the mass spectrometry result of polypeptide A. Figure 3 is the mass spectrometry result of polypeptide B. Figure 4 To control the peptide mass spectrometry results, Figures 2 to 4 The vertical axis represents the intensity of the ion peak, and the horizontal axis represents the ratio of mass to charge. Figures 2 to 4 It can be seen that the difference between the measured mass and the theoretical mass of the three peptides is within 10 ppm, and the sequence is correct.

[0053] Example 2

[0054] In this example, three healthy New Zealand rabbits were used for animal immunization experiments, which were commissioned to Hangzhou Jingjie Biotechnology Co., Ltd.

[0055] 1. Peptide coupling

[0056] The two modified polypeptides (polypeptide A and polypeptide B) in Example 1 were conjugated with KLH respectively and used for rabbit immunization. The polypeptide conjugation steps were:

[0057] (1) Dissolve 20 mg of SMCC in 2 ml of DMF.

[0058] (2) Add 0.8 ml of KLH to a 25 ml round-bottom flask and add 1× PBS (pH 7.2) to make the final protein concentration 15 mg / ml.

[0059] (3) Slowly add the dissolved SMCC solution dropwise to the 120 mg KLH protein system and stir at room temperature for 1 h.

[0060] (4) The cell culture medium was dialyzed against 1 L 1× PBS (pH 7.4) at 4°C for 6 h to remove free SMCC.

[0061] (5) Pour the dialyzed KLH protein into a 50 ml centrifuge tube, determine its volume using the scale on the centrifuge tube, calculate the concentration of the dialyzed protein based on the amount of KLH protein added before the reaction, and then transfer 2.5 mg of the KLH-SMCC solution into a 5 ml centrifuge tube based on its concentration.

[0062] (6) Dissolve 3.0 mg of the polypeptide in 0.6 ml of 1× PBS (pH 7.2) solution.

[0063] (7) Add the polypeptide solution dropwise into the KLH-SMCC tube and mix with a vertical mixer at room temperature for 4 hours.

[0064] 2. Rabbit Immunization

[0065] (1) Prepare immune materials

[0066] The modified polypeptides coupled in step 1 were mixed at a ratio of 1:1 to obtain an immunogen, which was diluted with physiological saline at a dilution factor of 15 times, and then mixed with the corresponding adjuvant (Freund's adjuvant) at a ratio of 1:1. The antigen and adjuvant were completely mixed to form a stable emulsion, and the antigen mixture was extracted with a syringe for rabbit immunization.

[0067] (2) Immunity

[0068] Antigens were injected at two points under the skin of the shoulders and two points in the muscles of the hind legs of the rabbits. Each area was injected with about 1 / 4 volume of the immunogen. Each rabbit was immunized 4 times in total, on the 1st day, 21st day, 28th day, and 35th day.

[0069] (3) Blood collection

[0070] Blood collection for the first time: On the 45th day, 30 mL of whole blood was collected and centrifuged (centrifugation parameters were 4000 rpm, 5 minutes). The supernatant was collected after centrifugation and sent to the laboratory for serum screening tests, including ELISA and Western blot;

[0071] Blood collection at the 2nd / 3rd / 4th time: Collect whole blood three times on the 50th day, 65th day, and 70th day, 20 mL each time, collect the supernatant after centrifugation and send it to the laboratory for serum screening tests, including ELISA and Western blot.

[0072] The rabbits immunized with a mixture of BAZ1B polypeptide A and BAZ1B polypeptide B were labeled R1, R2, and R3, respectively. The results of serum ELISA test on the 45th day are shown in Table 2.

[0073] Table 2 Serum ELISA test results

[0074]

[0075]

[0076] According to the results of ELISA testing of three rabbit sera in Table 2, the titers of recognition of modified peptides were all above 1:10K (OD>1).

[0077] The results of serum Western blot on day 45 are shown in Figure 5 According to the Western blot results, no band with the theoretical molecular weight of the target protein of about 175 kDa was detected in the serum of the three rabbits.

[0078] Based on the test results of ELISA and Western blot, sera from all three rabbits (with positive test results) were selected for purification.

[0079] 3. Antibody purification

[0080] (1) Prepare protein A affinity column:

[0081] Select 10mL of proteinA filler, mix and stir the filler with an equal volume of PBS buffer solution, and remove the bubbles in the filler by vacuuming. Slowly add proteinA filler into the glass column to prepare the chromatography column. Avoid column drying during this process. After filling, balance the column with 10 times the volume of pre-cooled PBS buffer solution.

[0082] (2) Protein A affinity chromatography:

[0083] After filtering the serum with a filter, load it onto a well-balanced protein A chromatography column. To detect the binding efficiency of the antiserum to the filler, retain the load effluent. Wash the column with PBS buffer solution, and then elute with 150mM pH3.4 glycine buffer (150mM pH3.4 glycine). Collect the eluate and add a neutralizing buffer solution to adjust the pH to 7.0.

[0084] (3) Enrichment of target antibodies:

[0085] The crude pure IgG obtained after protein A purification is loaded onto the balanced antigen polypeptide affinity chromatography column to specifically enrich the target antibody.

[0086] (4) Removal of non-specific antibodies:

[0087] The target antibody obtained in the previous step was loaded onto a non-modified affinity chromatography column, and the effluent (FT3) was directly collected to remove non-specific antibody components, thereby obtaining a polyclonal antibody against BAZ1B_K426hy.

[0088] (5) Antibody storage:

[0089] The protein content was determined. 10% glycerol was added to preserve the antibody, and the purified antibody was divided and stored at -20°C. The purified antibodies R1 to R3 were labeled Ab1 to Ab3, respectively.

[0090] Example 3

[0091] The purified anti-BAZ1B_K426hy polyclonal antibodies Ab1, Ab2 and Ab3 prepared in Example 2 were subjected to ELISA, Dotblot and Westernblot, respectively.

[0092] 1. ELISA test

[0093] (1) Antigen coating:

[0094] The antigen (antigen-modified polypeptide) was diluted 10 times with coating solution (PBS), and added to the ELISA plate in the amount of 50 μg / well, and kept in a refrigerator at 4°C overnight.

[0095] (2) Washing plate:

[0096] Take out the ELISA plate coated the day before, add 1×TBST for washing, fill the wells of the plate with washing solution, and wash 3 times in total.

[0097] (3) Closure:

[0098] Add 1% BSA blocking solution to the cleaned ELISA plate, fill each reaction well with the blocking solution, incubate at 37°C for 1 hour, then add 1×TBST washing solution again, fill the wells with the washing solution and wash twice in total.

[0099] (4) Primary antibody incubation:

[0100] The antibody was diluted in series starting from 1:1K, and the concentration after dilution is shown in Table 3. It was added to the ELISA plate in sequence, 100 μL per well, incubated at 37°C for 1.5 h, and then 1×TBST was added again for washing, and the washing solution was filled to the plate wells, and washed twice in total.

[0101] (5) Secondary antibody incubation:

[0102] The secondary antibody (rabbit antibody) was diluted to 1:10K with 100 μL of 1% BSA blocking solution, incubated at 37°C for 45 min, and then 1×TBST was added again for washing, and the washing solution was filled to the wells of the plate, and the washing was performed twice in total.

[0103] (6) Color rendering:

[0104] 100 μL of TMB colorimetric solution was added, and 100 μL of 1M sulfuric acid was added after 8 min to terminate the display reaction, and the data was read using an ELISA instrument. The results of the antibody ELISA test are shown in Table 3.

[0105] Table 3 Antibody ELISA test results

[0106]

[0107] The ELISA test results in Table 3 show that the recognition ability of the three antibodies for at least one modified polypeptide is not less than 1:50K dilution, and the hybridization signals of Ab1 and Ab3 recognizing the modified polypeptide are 10 times stronger than the hybridization signals recognizing the non-modified polypeptide.

[0108] 2. Dotblot detection

[0109] (1) Sample:

[0110] Uncross-linked antigen polypeptide A, antigen polypeptide A and non-modified polypeptide were spotted onto the PVDF membrane according to the gradient of 1ng, 4ng, 16ng and 64ng.

[0111] (2) Closure:

[0112] After the membrane surface is dry, add blocking solution (3-5 ml 5% skim milk) and block at room temperature for 60 minutes.

[0113] (3) Washing:

[0114] Wash with 1× TBST for 10 min.

[0115] (4) Primary antibody incubation:

[0116] The antibody was diluted with 5% skim milk powder to a concentration of 1:2000, incubated at room temperature for 2 h, and then washed three times with 1× TBST, each time for 8 min.

[0117] (5) Secondary antibody incubation:

[0118] Select rabbit antibody; add secondary antibody at a dilution ratio of 1:10K, incubate at room temperature for 1 hour, and wash 3 times with 1×TBST, each time for 8 minutes.

[0119] (6) Add 0.5-1 ml of color developing solution (Chemiluminescent HRP Substrate) to the washed membrane and then expose it to light.

[0120] Antibody Dotblot test results are shown in Figure 6 ,Depend on Figure 6 It can be seen that Ab1, Ab2, and Ab3 have no binding to the negative non-modified polypeptide, but have strong binding to the positive modified polypeptide, especially polypeptide A.

[0121] 3. Western blot detection

[0122] (1) Lysis of cells:

[0123] Select cells or tissues for testing according to experimental requirements, select different lysis methods according to different samples to obtain the total protein of the sample, and determine the protein concentration by BCA method:

[0124] Heat 1xHot Lysis Buffer: Heat 1xHot Lysis Buffer in a water bath to approximately 100°C.

[0125] Cells: Add 3 ml of boiled 1xHot lysis buffer to every 1 ml of cells (estimated amount of cell sediment), blow the cells apart with a pipette, boil the cells in a water bath, and continue to blow back and forth with a pipette until the cells appear as a transparent, clear, and uniform liquid. Tissues: Take an appropriate amount of tissue, chop it with scissors, add an appropriate amount of 1xHot lysis buffer, blow it, boil it in a water bath for at least 20 minutes, and blow it every 5 minutes.

[0126] Tips: The ratio of tissue to 1xHot lysis buffer should be adjusted according to the protein yield (for tissues with low protein content, reduce the amount of lysis buffer added).

[0127] The eyeball, pituitary gland, hippocampus and other low-yield tissues were added at a volume ratio of 1:2, and other high-yield tissues were added at a volume ratio of 1:3.

[0128] Ultrasonic disruption: 25% W for 5 min, 3 s per ultrasound, 5 s interval.

[0129] Tips: During the ultrasonic process, the sample must be placed in an ice-water mixture, the probe must be below the liquid surface, and the ultrasonic time must be less than the interval time to avoid bubbles. Each time a new cell or tissue is lysed, the probe must be ultrasonically cleaned with pure water for 3 seconds and gently wiped dry with dust-free paper to ensure no cross contamination.

[0130] Preparation of 1× Hot Lysis buffer (100 ml): 1 g SDS (1% w / v), 0.12 g Tris-base (10 mM), and 18 mg sodium vanadate (1.0 mM) were added to 80 ml deionized water in sequence. After the reagents were completely dissolved, the pH was adjusted to 8.0 with HCl and the volume was made up to 100 ml.

[0131] (2) Protein electrophoresis and membrane transfer:

[0132] Protein electrophoresis: Select 6% separation gel. Add 10% ammonium persulfate and TEMED at the end of the gel preparation, 4.7 mL of separation gel per plate. Load 20 μg of sample per well and perform electrophoresis; the electrophoresis conditions are: 80V for concentrated gel and 120V for separation gel.

[0133] Wet transfer: Cool the transfer solution before transfer, and lay the gel, membrane, and filter paper in the transfer solution to form a sandwich structure to avoid bubbles. The transfer voltage is 120V.

[0134] (3) Closure:

[0135] Add blocking solution (5% skim milk powder) to the transferred membrane and block at room temperature for 60 minutes. After incubation, wash with 1×TBST for 10 minutes.

[0136] (4) Primary antibody incubation:

[0137] The antibody was diluted with 5% skim milk powder (1:100 / 1:500), incubated at room temperature for 2 h, and then washed three times with 1×TBST, each time for 8 min.

[0138] (5) Secondary antibody incubation:

[0139] Select rabbit antibody; add secondary antibody at a dilution ratio of 1:10K, incubate at room temperature for 1 hour, and wash 3 times with 1×TBST, each time for 8 minutes.

[0140] (6) Add a color developing substrate to the washed membrane and then expose it to light.

[0141] The results of Western blot of antibodies are shown in Figure 7 , antibodies Ab1 and Ab2 detected the target band of about 175KDa in HeLa and MCF-7 cell lysates.

[0142] Ab1 was selected and confirmed by Western blot in HeLa and MCF-7 cell lysates. Figure 8 ,according to Figure 8The results of Western blot showed that Ab1 could detect the target band in HeLa and MCF-7 cell lysates. The positive detection limit of Dotblot reached 4ng, and the signal was 10 times stronger than that of the recognition of non-modified peptides. The results of Western blot experiments showed that antibody Ab1 could specifically recognize endogenous BAZ1B_K426hy protein.

[0143] Example 4

[0144] 1. Cell culture

[0145] MCF-7 cells (non-triple negative breast cancer cells): cultured in DMEM medium containing 10% FBS and 1% double antibody in a cell culture incubator at 37°C containing 5% CO2.

[0146] 2. Cell transfection

[0147] (1) Cell grouping

[0148] Experimental group 1: WSTF+si-NC, expression of WSTF and nonspecific siRNA control group;

[0149] Experimental group 2: WSTF+si-JMJD6, experimental group expressing WSTF and JMJD6 specific siRNA;

[0150] Experimental group 3: WSTF+JMJD6 WT, control group expressing WSTF and wild-type JMJD6;

[0151] Experimental group 4: WSTF+JMJD6 Mut, experimental group expressing WSTF and mutant JMJD6;

[0152] Experimental group 5: MCF-7 / WSTF - / - +si-NC, WSTF low expression and nonspecific siRNA control group;

[0153] Experimental group 6: MCF-7 / WSTF - / - +si-JMJD6, WSTF low expression and JMJD6 specific siRNA experimental group;

[0154] Experimental group 7: MCF-7 / WSTF - / - +JMJD6 WT, WSTF low expression and wild-type JMJD6 control group;

[0155] Experimental group 8: MCF-7 / WSTF - / - +JMJD6 Mut, experimental group with low WSTF expression and mutant JMJD6;

[0156] (2) Cell inoculation: MCF-7 or MCF-7 / WSTF cells in the logarithmic growth phase were seeded - / - Cells (cell lines with knockdown of WSTF) were seeded in 6-well plates, and the density was about 60-70% at the time of transfection the next day;

[0157] (3) Preparation of transfection solution: Prepare transfection solution A and B in a sterile 1.5 mL centrifuge tube.

[0158] Preparation of Solution A:

[0159] Experimental group 1A solution: dilute 0.5 μg WSTF and 0.5 μL si-NC with serum-free medium Opti-MEM and add Opti-MEM serum-free medium to a final volume of 50 μL, and mix gently;

[0160] Experimental group 2A solution: dilute 0.5 μg WSTF and 0.5 μL si-JMJD6 with serum-free medium Opti-MEM and add Opti-MEM serum-free medium to a final volume of 50 μL, and mix gently;

[0161] Experimental group 3A solution: dilute 0.5 μg WSTF and 0.5 μL JMJD6 WT with serum-free medium Opti-MEM, add Opti-MEM serum-free medium to a final volume of 50 μL, and mix gently;

[0162] Experimental group 4A solution: dilute 0.5 μg WSTF and 0.5 μL JMJD6 Mut with serum-free medium Opti-MEM and add Opti-MEM serum-free medium to a final volume of 50 μL, and mix gently;

[0163] Experimental group 5A solution: 0.5 μg MCF-7 / WSTF diluted in serum-free medium Opti-MEM - / - and 0.5 μL si-NC were added to Opti-MEM serum-free medium to a final volume of 50 μL and gently mixed;

[0164] Experimental group 6A solution: 0.5 μg MCF-7 / WSTF diluted in serum-free medium Opti-MEM - / - and 0.5 μL si-JMJD6 were added to Opti-MEM serum-free medium to a final volume of 50 μL and gently mixed;

[0165] Experimental group 7A solution: 0.5 μg MCF-7 / WSTF diluted in serum-free medium Opti-MEM - / - and 0.5 μL JMJD6WT were added to Opti-MEM serum-free medium to a final volume of 50 μL and gently mixed;

[0166] Experimental group 8A solution: 0.5 μg MCF-7 / WSTF diluted in serum-free medium Opti-MEM - / - and 0.5 μL JMJD6Mut were added to Opti-MEM serum-free medium to a final volume of 50 μL and gently mixed;

[0167] Preparation of liquid B: Gently mix the liposomes before use. Add 1 μL of lipofectamine 2000 to Opti-MEM serum-free medium to a final volume of 50 μL, gently mix, and incubate at room temperature for 5 minutes.

[0168] Add solution B to solution A in each experimental group, flick to mix, and incubate at room temperature for 20 min.

[0169] The mixed solution was evenly and slowly added dropwise to the above culture bottle and mixed, cultured in a 5% CO2 incubator at 37°C for 5 h, and then replaced with normal culture medium for continued culture.

[0170] 3. Transwell assay to detect the invasion ability of each group of cells

[0171] (1) The cell culture medium of each group was completely discarded, and the cells were washed once with PBS. After digestion, a digestion solution (0.02% EDTA, 0.25% trypsin) was added to each well. DMEM culture medium containing 10% FBS was added to terminate the digestion, and the cells were mixed by pipetting for the Transwell experiment.

[0172] (2) Apply 10 μL of fibronectin (0.5 mg / mL) to the bottom of each Transwell chamber and air-dry in a clean bench to solidify the fibronectin on the bottom of the membrane.

[0173] (3) Dissolve the matrix gel and add 50 μL of gel to each well. Digest and count the cells in each group at the same time. Take 10 5 Place cells in a 1.5 mL EP tube, centrifuge at 2000 rpm for 5 minutes, remove the supernatant, add 200 μL serum-free DMEM medium to resuspend the cells, and add them to the Transwell chamber. Add DMEM medium containing 20% ​​Gibico serum to the lower chamber and culture in a 37°C incubator for 24 hours.

[0174] (4) Remove the Transwell chamber, wipe the cells inside with a cotton swab, and gently wash away the remaining cells with PBS. Prepare a mixture of methanol and glacial acetic acid in a ratio of 3:1, and fix the cells on the back of the Transwell chamber for 30 minutes. Place in crystal violet staining solution and stain for 15 minutes. Wash and fix the membrane on a slide for easy observation.

[0175] (5) Take three random fields of view under the microscope, take pictures and draw a bar graph for analysis. The results are shown in Fig. 9.

[0176] Depend on Fig. 9 It can be seen that JMJD6-WSTF K426hy Axis regulates cell invasion ability.

[0177] 4. Clone formation experiment to detect the clone formation ability of each group of cells

[0178] (1) The cell culture medium of each group was completely discarded, and the cells were washed once with PBS. After digestion, a digestion solution (0.02% EDTA, 0.25% trypsin) was added to each well. DMEM culture medium containing 10% FBS was added to terminate the digestion and the cells were mixed by pipetting to perform a cloning experiment.

[0179] (2) Count the cells in each group, take 300 cells and inoculate them into 12-well plates, add 2 mL of complete medium and culture in a 37°C, 5% CO2 incubator for 1 to 2 weeks.

[0180] (3) When the number of cells in each clone has grown to more than 50, discard the complete medium, wash the cells once with PBS, add 500 μL of 4% paraformaldehyde to each well to fix the cells, incubate at 4°C for 30 min, wash the cells once with PBS, add 500 μL of 0.1% crystal violet to each well for staining, and rinse with water.

[0181] (5) After the culture plate is dried, take a picture with a camera and draw a bar graph for analysis. The results are shown in Fig.10 .

[0182] Depend on Fig.10 It can be seen that JMJD6-WSTF K426hy Axis regulates cell clone-forming ability.

[0183] Example 5

[0184] The purified anti-BAZ1B_K426hy polyclonal antibody Ab1 prepared in Example 2 was used to detect the expression level of hydroxylated WSTF (BAZ1B).

[0185] 1. Cell culture

[0186] MCF-7 cells: cultured in DMEM containing 10% FBS and 1% double antibody in a cell culture incubator at 37°C and 5% CO2.

[0187] 2. Cell transfection

[0188] (1) Cell grouping

[0189] Experimental group 1: WSTF+si-NC, expression of WSTF and nonspecific siRNA control group;

[0190] Experimental group 2: WSTF+si-JMJD6, experimental group expressing WSTF and JMJD6 specific siRNA;

[0191] Experimental group 3: WSTF+JMJD6 WT, control group expressing WSTF and wild-type JMJD6;

[0192] Experimental group 4: WSTF+JMJD6 Mut, experimental group expressing WSTF and mutant JMJD6;

[0193] Experimental group 5: MCF-7 / WSTF - / - +si-NC, WSTF low expression and nonspecific siRNA control group;

[0194] Experimental group 6: MCF-7 / WSTF - / - +si-JMJD6, WSTF low expression and JMJD6 specific siRNA experimental group;

[0195] Experimental group 7: MCF-7 / WSTF - / - +JMJD6 WT, WSTF low expression and wild-type JMJD6 control group;

[0196] Experimental group 8: MCF-7 / WSTF - / - +JMJD6 Mut, experimental group with low WSTF expression and mutant JMJD6;

[0197] (2) Cell inoculation: MCF-7 or MCF-7 / WSTF cells in the logarithmic growth phase were seeded - / - Cells (cell lines with knockdown of WSTF) were seeded in 6-well plates, and the density was about 60-70% at the time of transfection the next day;

[0198] (3) Preparation of transfection solution: Prepare transfection solution A and B in a sterile 1.5 mL centrifuge tube.

[0199] Preparation of Solution A:

[0200] Experimental group 1A solution: dilute 1.5 μg WSTF and 1.5 μL si-NC with serum-free medium Opti-MEM and add Opti-MEM serum-free medium to a final volume of 50 μl, and mix gently;

[0201] Experimental group 2A solution: dilute 1.5 μg WSTF and 1.5 μL si-JMJD6 with serum-free medium Opti-MEM and add Opti-MEM serum-free medium to a final volume of 50 μl, and mix gently;

[0202] Experimental group 3A solution: dilute 1.5 μg WSTF and 1.5 μL JMJD6 WT with serum-free medium Opti-MEM and add Opti-MEM serum-free medium to a final volume of 50 μl, and mix gently;

[0203] Experimental group 4A solution: dilute 1.5 μg WSTF and 1.5 μL JMJD6 Mut with serum-free medium Opti-MEM and add Opti-MEM serum-free medium to a final volume of 50 μl, and mix gently;

[0204] Experimental group 5A solution: 1.5 μg MCF-7 / WSTF diluted in serum-free medium Opti-MEM - / - and 1.5 μL si-NC were added to Opti-MEM serum-free medium to a final volume of 50 μl and gently mixed;

[0205] Experimental group 6A solution: 1.5 μg MCF-7 / WSTF diluted in serum-free medium Opti-MEM - / - and 1.5 μL si-JMJD6 were added to Opti-MEM serum-free medium to a final volume of 50 μl and gently mixed;

[0206] Experimental group 7A solution: 1.5 μg MCF-7 / WSTF diluted in serum-free medium Opti-MEM - / - and 1.5 μL JMJD6WT were added to Opti-MEM serum-free medium to a final volume of 50 μl and gently mixed;

[0207] Experimental group 8A solution: 1.5 μg MCF-7 / WSTF diluted in serum-free medium Opti-MEM - / - and 1.5 μL JMJD6Mut were added to Opti-MEM serum-free medium to a final volume of 50 μl and gently mixed;

[0208] Preparation of solution B: dilute 3 μL of Lipofectamine 2000 Reagent with serum-free culture medium Opti-MEM to a final volume of 50 μL, mix gently, and let stand at room temperature for 5 min.

[0209] Add solution B dropwise into solution A of each experimental group, mix gently, and let stand at room temperature for 20 min.

[0210] (4) Transfection: Add transfection solution to the corresponding wells, 100 μL / well, add 600 μL Opti-MEM to each well, shake the culture plate gently to make it evenly distributed, and then culture in a cell culture incubator at 37°C and 5% CO2.

[0211] After 4 hours, each well was replaced with 3 mL of complete culture medium containing 10% FBS (without antibiotics), and culture was continued in a cell culture incubator at 37° C. with 5% CO 2 .

[0212] 3. WB detection of the expression level of hydroxylated WSTF

[0213] (1) Lysis of cell nuclei: After 48 h, the original culture medium of the transfected cells in each experimental group was discarded (6-well plate), and the cells were washed once with 1× PBS. Then, 1 mL of 0.05% trypsin was added for digestion. The cells were blown with 1 mL of complete culture medium and collected in a 1.5EP tube. The cells were centrifuged at 2000 rpm for 5 min, resuspended and rinsed once with PBS, and the supernatant was completely discarded. Then, 150 μL of 0.4% NP-40 (containing protease inhibitor cocktail) was added, vortexed for 5 min, and centrifuged at 5000 rpm at 4°C for 10 min to precipitate the cell nuclei. 100 μL of 0.1% NP-40 (containing protease inhibitor cocktail) was added thereto, and the cells were flicked to mix. The cells were centrifuged at 5000 rpm at 4°C for 10 min, and the supernatant was completely discarded. 100 μL of RIPA was added, and the cells were thoroughly mixed and dispersed. The cells were frozen and thawed once at -80°C to obtain nuclear proteins.

[0214] (2) Prepare SDS denatured 6% polyacrylamide gel (lower separation gel, single-sided)

[0215] Table 4 6% polyacrylamide gel formula

[0216]

[0217] After mixing, quickly pour the gel to about 2 / 3 of the total height of the glass plate, then add 1 mL of water-saturated n-butanol on top of the gel to ensure the smoothness of the upper layer of the gel, and let it stand until the gel solidifies.

[0218] (3) Prepare SDS denatured 5% polyacrylamide gel (top stacking gel, single side)

[0219] Table 5 5% polyacrylamide gel formula

[0220]

[0221]

[0222] After mixing, quickly pour the gel until the glass plate is filled, insert the comb, and let it stand until the gel solidifies. Remove the comb before electrophoresis, place the gel in 1× Tris-glycine electrophoresis buffer, and blow clean the sample well with a syringe needle.

[0223] (4) After mixing the protein sample with 5× loading buffer (containing β-mercaptoethanol), boil and denature for 5 min, and place on ice for 5 min. Take an appropriate amount of protein sample and load it on SDS denaturing 6% polyacrylamide gel electrophoresis until the target protein is effectively separated and then stop electrophoresis.

[0224] (5) After electrophoresis, the gel is removed and placed in a sandwich holder for transfer. The gel is placed at the negative electrode and the PVDF membrane is placed at the positive electrode. The membrane is transferred in a transfer buffer at 4°C and 350 mA for 2 h to transfer the proteins in the gel to the PVDF membrane to form a blot.

[0225] (6) Place the membrane in 1× Blotto and block with shaking at room temperature for 2 h.

[0226] (7) The membrane was cut open at the protein blotting position and placed in Blotto containing the corresponding primary antibody (the purified polyclonal antibody Ab1 prepared in Example 2) and shaken at 4°C overnight.

[0227] (8) Place the membrane in 1× TBST solution and rinse with shaking for 5 min, for a total of 4 times.

[0228] (9) Place the membrane in Blotto containing the corresponding secondary antibody (HRP-labeled goat anti-rabbit IgG antibody) at room temperature for 1.5 h.

[0229] (10) Place the membrane in 1× TBST solution and rinse with shaking for 5 min, for a total of 4 times.

[0230] (11) Place the membrane in Western LightningTM Chemiluminescence Reagent for 30 seconds.

[0231] (12) Immediately place the membrane in an exposure box and expose the photosensitive film in a dark room for 1 min, followed by development and fixing.

[0232] (13) The film was photographed using the LabWorksTM gel imaging and analysis system, and the brightness values ​​of the target bands in each group were analyzed. The method was to calculate the ratio of the brightness value of the target band of each sample to the brightness value of the corresponding LMNB1 (internal reference) band to obtain the corrected brightness value of the target band. The control group was taken as the standard value 1, and a bar graph was drawn. The results are shown in Fig.11 .

[0233] Depend on Fig.11 It can be seen that after JMJD6 knockdown or mutation, the WSTF hydroxylation level was significantly reduced.

[0234] The results of Examples 4 and 5 show that Lys426 hydroxylation (K426Hy) can inhibit the transcriptional regulatory activity of WSTF and induce its degradation. In breast cancer cells, JMJD6 can negatively regulate the transcription factor activity and stability of WSTF through hydroxylation modification, thereby affecting the occurrence and development of tumors.

[0235] Example 6

[0236] The purified anti-BAZ1B_K426hy polyclonal antibody Ab1 prepared in Example 2 was used to detect the expression level of hydroxylated WSTF (BAZ1B) in different cells.

[0237] 1. Cell culture

[0238] Beas-2B (normal human lung epithelial cells): cultured in DMEM containing 10% FBS and 1% double antibody in a cell culture incubator at 37°C and 5% CO2;

[0239] A549 (human lung cancer cells): cultured in Ham's F-12K medium containing 10% FBS and 1% double antibody in a cell culture incubator at 37°C and 5% CO2;

[0240] MDA-MB-231 (human triple-negative breast cancer cells): cultured in DMEM containing 10% FBS and 1% double antibody in a cell culture incubator at 37°C and 5% CO2;

[0241] SW620 (human colorectal cancer cells): cultured in DMEM containing 10% FBS and 1% double antibody in a cell culture incubator at 37°C and 5% CO2;

[0242] A375 (human melanoma cells): cultured in DMEM containing 10% FBS and 1% double antibody in a cell culture incubator at 37°C and 5% CO2;

[0243] MGC-803 (human gastric cancer cells): cultured in 1640 culture medium containing 10% FBS and 1% double antibody in a cell culture incubator at 37°C and 5% CO2;

[0244] HeLa (human cervical cancer cells): cultured in 1640 culture medium containing 10% FBS and 1% double antibody in a cell culture incubator at 37°C and 5% CO2;

[0245] U251 (human glioma cells): cultured in DMEM / F12 medium containing 10% FBS and 1% double antibody in a cell culture incubator at 37°C and 5% CO2;

[0246] Eca-109 (human esophageal cancer cells): cultured in 1640 culture medium containing 10% FBS and 1% double antibody in a cell culture incubator at 37°C and 5% CO2;

[0247] IOSE80 (normal human ovarian epithelial cells): cultured in 1640 culture medium containing 10% FBS and 1% double antibody in a cell culture incubator at 37°C and 5% CO2;

[0248] OV2008 (human ovarian cancer cells): cultured in DMEM containing 10% FBS and 1% double antibody in a cell culture incubator at 37°C and 5% CO2;

[0249] PANC1 (human pancreatic cancer cells): cultured in DMEM medium containing 10% FBS and 1% double antibody in a cell culture incubator at 37°C containing 5% CO2.

[0250] 2. Nuclear protein extraction

[0251] Cell collection: Wash each cell in a 100 mL bottle once with 1×PBS, digest with digestion solution (0.02% EDTA, 0.05% trypsin), add complete culture medium containing 10% FBS to terminate digestion and mix the cells by pipetting, centrifuge at 2000 rpm for 5 min, resuspend and rinse once with PBS, and discard the supernatant completely.

[0252] Add 450 μL of 0.4% NP-40 (containing protease inhibitor cocktail), vortex mix for 5 minutes, centrifuge at 4℃5000rpm for 10 minutes, precipitate the cell nucleus, add 300 μL of 0.1% NP-40 (containing protease inhibitor cocktail), flick to mix, centrifuge at 4℃5000rpm for 10 minutes, discard the supernatant, add 200 μL of RIPA, mix thoroughly, freeze and thaw once at -80℃ to obtain the nuclear protein.

[0253] 3. WB detection of the expression level of hydroxylated WSTF

[0254] (1) Prepare SDS denatured 10% polyacrylamide gel (lower separation gel, single-sided):

[0255] Table 6 6% polyacrylamide gel formula

[0256]

[0257] After mixing, quickly pour the gel to about 2 / 3 of the total height of the glass plate, then add 1 mL of water-saturated n-butanol on top of the gel to ensure the smoothness of the upper layer of the gel, and let it stand until the gel solidifies.

[0258] (2) Prepare SDS denatured 5% polyacrylamide gel (top stacking gel, single side)

[0259] Table 7 5% polyacrylamide gel formula

[0260]

[0261] After mixing, quickly pour the gel until the glass plate is filled, insert the comb, and let it stand until the gel solidifies. Remove the comb before electrophoresis, place the gel in 1× Tris-glycine electrophoresis buffer, and blow clean the sample well with a syringe needle.

[0262] (3) After mixing the protein sample with 5× loading buffer (containing β-mercaptoethanol), boil and denature for 5 min, and place on ice for 5 min. Take an appropriate amount of protein sample and load it on SDS-denatured 10% polyacrylamide gel electrophoresis (SDS-PAGE) until the target protein is effectively separated and then stop the electrophoresis.

[0263] (4) After electrophoresis, the gel is removed and placed in a sandwich holder for membrane transfer. The gel is placed at the negative electrode and the PVDF membrane is placed at the positive electrode. The membrane is transferred in a transfer buffer at 4°C and 350 mA for 2 h to transfer the proteins in the gel to the PVDF membrane to form a blot.

[0264] (5) Place the membrane in 1× Blotto and block with shaking at room temperature for 2 h.

[0265] (6) The membrane was cut open at the protein blotting position and placed in Blotto containing the corresponding primary antibody (the purified polyclonal antibody Ab1 prepared in Example 2) and shaken at 4°C overnight.

[0266] (7) Place the membrane in 1× TBST solution and rinse with shaking for 5 min, for a total of 4 times.

[0267] (8) Place the membrane in Blotto containing the corresponding secondary antibody (HRP-labeled goat anti-rabbit IgG antibody) at room temperature for 1.5 h.

[0268] (9) Place the membrane in 1× TBST solution and wash with shaking for 5 min, for a total of 4 times.

[0269] (10) Place the membrane in Western LightningTM Chemiluminescence Reagent for 30 seconds.

[0270] (11) Immediately place the membrane in an exposure box and expose the photosensitive film in a dark room for 1 min, followed by development and fixing.

[0271] (12) The film was photographed using the LabWorksTM gel imaging and analysis system, and the brightness values ​​of the target bands in each group were analyzed. The method was to calculate the ratio of the brightness value of the target band of each sample to the brightness value of the corresponding LMNB1 (internal reference) band to obtain the corrected brightness value of the target band. The control group was taken as the standard value 1, and a bar graph was drawn. The results are shown in Fig.12 .

[0272] Depend on Fig.12 It can be seen that the expression level of BAZ1B_K426hy in normal human cells is almost stable, and the expression level of BAZ1B_K426hy in tumor cells is significantly different from that in normal cells. This shows that the occurrence of tumors can be diagnosed by detecting the expression level of BAZ1B_K426hy.

[0273] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. Use of a polyclonal antibody against BAZ1B_K426hy in the preparation of a reagent for assessing tumor risk, characterized in that: The method for preparing the polyclonal antibody comprises: A polypeptide A having a sequence of SKSPK-hydroxyl K-GLKTP and a polypeptide B having a sequence of NSKSPK-hydroxyl K-GLKTPK are coupled to KLH respectively, and the coupled polypeptide solutions are mixed at a volume ratio of 1-2:1-2 and used for animal immunization, and the serum of the immunized animals is collected and purified to obtain a polyclonal antibody against BAZ1B_K426hy; The animal is a rabbit; The tumors are lung cancer and ovarian cancer.

2. The use according to claim 1, characterized in that: The animal is immunized 3 to 5 times.